A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria

Clinical trial NCT05528861 · TERMINATED

Trial details

NCT number: NCT05528861
Sponsor: Allakos Inc.
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Chronic Spontaneous Urticaria

Start date: 2022-10-26
Primary completion: 2023-12-27
Enrollment: 127

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.